Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)

Background: Clinical oncology is the main application of 18F-deoxyglucose (FDG) positron emission tomography (PET). Aim: To evaluate the first 1,000 patients studied with FDG PET in Chile. Material and methods: Retrospective analysis of 1,000 patients (aged between 1 and 94 years, 550 females) studi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Massardo,Teresa, Jofré,M. Josefina, Sierralta,Paulina, Canessa,José, González,Patricio, Humeres,Pamela, Valdebenito,Robert
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2007
Materias:	Oncology, radiation Positron-emission tomography Tomography, emission-computed
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000300014
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872007000300014
record_format	dspace
spelling	oai:scielo:S0034-988720070003000142014-01-06Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)Massardo,TeresaJofré,M. JosefinaSierralta,PaulinaCanessa,JoséGonzález,PatricioHumeres,PamelaValdebenito,Robert Oncology, radiation Positron-emission tomography Tomography, emission-computed Background: Clinical oncology is the main application of 18F-deoxyglucose (FDG) positron emission tomography (PET). Aim: To evaluate the first 1,000 patients studied with FDG PET in Chile. Material and methods: Retrospective analysis of 1,000 patients (aged between 1 and 94 years, 550 females) studied with FDG PET, since 2003. All studies were performed in a high resolution Siemens Ecat-Exact HR (+). All reports were based on the visual analysis of three plane and three-dimensional images. Results: Ninety seven percent of exams were done for oncological indications, mainly lung lesions, lymphoma, colorectal and gastroesophageal, cancer and breast tumors. Only 1% of patients had brain tumors. Non tumor neurological indications corresponded to 1.7%. Cardiac studies were only 0.3% and inflammatory process corresponded to 1%. The 5.6% corresponded to pediatric population. Six percent of patients were aged less than 18 years and in 50% of them, the indication was oncological, mainly lymphomas, brain tumors, endocrine cancers and sarcomas. The remaining 50% had a neurological indications, mainly for refractory epilepsy. Conclusions: PET FDG imaging was effective in the management of diverse diseases of children and adultsinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.135 n.3 20072007-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000300014es10.4067/S0034-98872007000300014
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Oncology, radiation Positron-emission tomography Tomography, emission-computed
spellingShingle	Oncology, radiation Positron-emission tomography Tomography, emission-computed Massardo,Teresa Jofré,M. Josefina Sierralta,Paulina Canessa,José González,Patricio Humeres,Pamela Valdebenito,Robert Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)
description	Background: Clinical oncology is the main application of 18F-deoxyglucose (FDG) positron emission tomography (PET). Aim: To evaluate the first 1,000 patients studied with FDG PET in Chile. Material and methods: Retrospective analysis of 1,000 patients (aged between 1 and 94 years, 550 females) studied with FDG PET, since 2003. All studies were performed in a high resolution Siemens Ecat-Exact HR (+). All reports were based on the visual analysis of three plane and three-dimensional images. Results: Ninety seven percent of exams were done for oncological indications, mainly lung lesions, lymphoma, colorectal and gastroesophageal, cancer and breast tumors. Only 1% of patients had brain tumors. Non tumor neurological indications corresponded to 1.7%. Cardiac studies were only 0.3% and inflammatory process corresponded to 1%. The 5.6% corresponded to pediatric population. Six percent of patients were aged less than 18 years and in 50% of them, the indication was oncological, mainly lymphomas, brain tumors, endocrine cancers and sarcomas. The remaining 50% had a neurological indications, mainly for refractory epilepsy. Conclusions: PET FDG imaging was effective in the management of diverse diseases of children and adults
author	Massardo,Teresa Jofré,M. Josefina Sierralta,Paulina Canessa,José González,Patricio Humeres,Pamela Valdebenito,Robert
author_facet	Massardo,Teresa Jofré,M. Josefina Sierralta,Paulina Canessa,José González,Patricio Humeres,Pamela Valdebenito,Robert
author_sort	Massardo,Teresa
title	Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)
title_short	Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)
title_full	Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)
title_fullStr	Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)
title_full_unstemmed	Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)
title_sort	análisis de 1.000 casos de estudios metabólicos en chile con pet 18flúor-deoxiglucosa (fdg)
publisher	Sociedad Médica de Santiago
publishDate	2007
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000300014
work_keys_str_mv	AT massardoteresa analisisde1000casosdeestudiosmetabolicosenchileconpet18fluordeoxiglucosafdg AT jofremjosefina analisisde1000casosdeestudiosmetabolicosenchileconpet18fluordeoxiglucosafdg AT sierraltapaulina analisisde1000casosdeestudiosmetabolicosenchileconpet18fluordeoxiglucosafdg AT canessajose analisisde1000casosdeestudiosmetabolicosenchileconpet18fluordeoxiglucosafdg AT gonzalezpatricio analisisde1000casosdeestudiosmetabolicosenchileconpet18fluordeoxiglucosafdg AT humerespamela analisisde1000casosdeestudiosmetabolicosenchileconpet18fluordeoxiglucosafdg AT valdebenitorobert analisisde1000casosdeestudiosmetabolicosenchileconpet18fluordeoxiglucosafdg
_version_	1718436312183209984

Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)

Ejemplares similares